TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29966038
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg) alone
Study: 30358565
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose oseltamivir (SD)
Study: 30358565
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose oseltamivir (DD)
Study: 27041244
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day rosuvastatin (R group, n=26)
Study: 27041244
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day rosuvastatin plus 2 g/day of ω-3 PUFAs (R+O group, n=24)
Study: 24928218
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed varenicline therapy
Study: 24928218
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (self-administered varenicline)
Study: 22010847
Drug: Agaricus blazei
Normalized name: AGARICUS BLAZEI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus blazei Murrill (AbM) dry extract, 900 mg/day for 60 days
Study: 20467879
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine administered for 60 min
Study: 8626261
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing (6 mg/kg)
Study: 8626261
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily dosing (6 mg/kg)
Study: 30946860
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg cortisol
Study: 15353142
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET EN) 200 mg used as a 2‐monthly injection
Study: 9599191
Drug: Protein supplementation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation, 20 g/d
Study: 8023348
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg/d PO for 21 days
Study: 2661606
Drug: Benztropine 4
Normalized name: benztropine 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine 4 mg/day
Study: 28988240
Drug: Intensive 1-year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive 1-year lifestyle treatment with 2 months inpatient period (short-stay group)
Study: 28988240
Drug: Intensive 1-year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive 1-year lifestyle treatment with 6 months inpatient period (long-stay group)
Study: 28988240
Drug: Short-stay treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stay treatment
Study: 28988240
Drug: Long-stay treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-stay treatment
Study: 24076103
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine digluconate solution applied for 30s after etching
Study: 21518686
Drug: RenalGuard System
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenalGuard System treatment
Study: 18356834
Drug: Standard group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group-based behavioral treatment
Study: 4038550
Drug: Intravenous droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous droperidol
Study: 8618770
Drug: 0.02% (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% (0.2 mg/ml) mitomycin C for 5 minutes
Study: 6398861
Drug: Halopemide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halopemide (2 X 10 mg/day)
Study: 6398861
Drug: Halopemide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halopemide (2 X 20 mg/day)
Study: 23859303
Drug: amlodipine/benazepril 2.5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine/benazepril 2.5/10 mg
Study: 23859303
Drug: amlodipine/benazepril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine/benazepril 5/10 mg
Study: 23859303
Drug: benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg
Study: 23497111
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine)
Study: 12241634
Drug: Partial median
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial median and ulnar nerve transfer; specific details on dosage and duration not available.
Study: 12241634
Drug: Phrenic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic and spinal accessary nerve transfer; specific details on dosage and duration not available.
Study: 8087937
Drug: ATP‐MgCl2 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP‐MgCl2 (0.1 mg/kg/min)
Study: 8087937
Drug: Tolazoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolazoline (1 mg/kg)
Study: 2503148
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (orthovoltage treatment)
Study: 361132
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy as an adjunct to surgery
Study: 31779056
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of quadrivalent influenza vaccine
Study: 31779056
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of trivalent influenza vaccine
Study: 29851024
Drug: 8 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL/kg Ringer's acetate solution before the induction of anaesthesia
Study: 18635722
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg/day
Study: 1564540
Drug: Intravenous BCNU
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous BCNU
Study: 1564540
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil
Study: 3970647
Drug: Pindolol (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (dosage not specified)
Study: 27843418
Drug: CHO ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO ingestion at 15 g/h
Study: 27843418
Drug: CHO ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO ingestion at 60 g/h
Study: 24238825
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (2 g)
Study: 18814408
Drug: Phytotherapy (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapy (herbal medicine)
Study: 16075255
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) using propofol/remifentanil
Study: 12430113
Drug: Patient-Controlled Femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Femoral Analgesia (PCFA) with 0.2% ropivacaine (boluses of 10 mL with a lockout time of 60 minutes)
Study: 12430113
Drug: Continuous Femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Femoral Infusion (Inf) with 0.2% ropivacaine (10 mL/h)
Study: 12430113
Drug: PCFA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCFA + Inf with 0.2% ropivacaine (5 mL/h plus boluses of 5 mL with a lockout time of 60 minutes)
Study: 28498207
Drug: No secondary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No secondary injection
Study: 23748819
Drug: MA plus
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21)
Study: 23748819
Drug: meloxicam plus
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam plus oral EPA-enriched nutritional supplement (n = 18)
Study: 20655544
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment with peer-enhanced adventure therapy
Study: 20655544
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral weight control treatment with supervised aerobic exercise
Study: 18209781
Drug: 5-HTP 100
Normalized name: CVS 5-HTP 100mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP 100 mg/day
Study: 11906645
Drug: GM-CSF-stimulated peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF-stimulated peripheral blood stem cell (PBSC) infusion with cyclosporin A (CsA) and 0.4 mg/kg prednisolone
Study: 11906645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received azathioprine, 1 mg/kg prednisolone, and CsA
Study: 29982723
Drug: High-Intensity Sweeteners
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Sweeteners Beverage (HISB) - 2 cans (330 mL each)/d for 12 weeks
Study: 29982723
Drug: Unsweetened Beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsweetened Beverage (UB) - 2 cans (330 mL each)/d for 12 weeks
Study: 20224007
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum strain WCFS1 administered in the duodenum for 6 hours via feeding catheter
Study: 20224007
Drug: TLR2 agonist
Normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR2 agonist Pam(3)‐Cys‐SK4 (PCSK)
Study: 16389694
Drug: Exenatide (glucagon‐like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (glucagon‐like peptide‐1 agonist)
Study: 11879382
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg LTG
Study: 11879382
Drug: VPA 900
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA 900 mg
Study: 10229128
Drug: IgM antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibodies to nerve glycoconjugates
Study: 7887643
Drug: FP (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (400 mg/m2 UFT po daily and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Study: 7887643
Drug: FEP (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP (400 mg/m2 UFT po daily, 50 mg/m2 etoposide iv and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Study: 2167953
Drug: Cisplatin (CDDP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP; 120 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Study: 2167953
Drug: Carboplatin (CBDCA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (CBDCA; 325 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Study: 598412
Drug: Digoxin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.4 mg i.v. daily for 14 days
Study: 598412
Drug: Beta-methyldigoxin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-methyldigoxin 0.4 mg i.v. daily for 14 days
Study: 31801679
Drug: TWHF 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TWHF 60 mg/d plus valsartan 160 mg/d
Study: 23530837
Drug: Subcutaneous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tissue closure with staples
Study: 23530837
Drug: Subcutaneous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tissue closure with intracutaneous sutures
Study: 23530837
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous tissue closure with staples
Study: 23530837
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous tissue closure with intracutaneous sutures
Study: 21632811
Drug: Early metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early metformin (study years 1-4; age 8-12 years)
Study: 21632811
Drug: Late metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late metformin (year 6; age 13-14 years)
Study: 10632907
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (Group S)
Study: 10632907
Drug: Multiple fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple fractionated doses (Group M)
Study: 28263288
Drug: Non-adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted influenza vaccine
Study: 15846270
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 530)
Study: 12224004
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (DaunoXome) combined with high-dose arabinosyl cytosine (HDAC)
Study: 9626770
Drug: Chimeric anti-CD4
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-CD4 antibody treatment
Study: 9039623
Drug: Dynamic contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic contrast-enhanced MR imaging with gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA) at a dosage of 0.1 mmol/kg body weight.
Study: 9039623
Drug: MR imaging
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR imaging follow-up during therapy in patients with B-CLL.
Study: 4812364
Drug: Aspirin 15
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 15 mg/kg per dose for 5 doses
Study: 4812364
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (open arteriotomy or no aspirin)
Study: 23884826
Drug: Ephedrine bolus
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine bolus 5 mg plus ephedrine infusion
Study: 23884826
Drug: Ephedrine bolus
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine bolus 5 mg plus normal saline infusion
Study: 19666643
Drug: candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan 8 mg/day
Study: 15165934
Drug: candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan 16 mg/day
Study: 15848527
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil (MMF), prednisone, daclizumab, and reduced CsA dose (5 mg per kg per day for 7 months followed by complete withdrawal)
Study: 15848527
Drug: normal CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal CsA dose (10 mg per kg per day adjusted according to C2 levels), MMF, prednisone, and no daclizumab
Study: 11548984
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (Rebif) 44 mcg subcutaneously three times per week
Study: 11548984
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (Rebif) 22 mcg subcutaneously three times per week
Study: 9505784
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (group D)
Study: 3275748
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) to 20 Gy using high‐energy electrons followed by low‐dose (35 to 40 Gy) postoperative external beam irradiation
Study: 3275748
Drug: High‐dose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose (50 to 55 Gy) postoperative external beam irradiation
Study: 22483593
Drug: Ultrasound-guided subacromial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided subacromial injection with triamcinolone 40mg
Study: 12017396
Drug: nimesulide-beta-cyclodextrin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide-beta-cyclodextrin (400 mg BID, orally = 100 mg nimesulide BID)
Study: 10492407
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine and 10 mg preservative-free pethidine (group LP)
Study: 10492407
Drug: 2% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine, 10 mg preservative-free pethidine and 20 mg tenoxicam (group LPT)
Study: 8934067
Drug: Uniplant contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniplant contraceptive implant
Study: 30413181
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose antibiotics
Study: 24852946
Drug: Erythritol candy
Normalized name: Erythritol
DrugBank: Erythritol (DB04481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol candy (7.5 g daily intake)
Study: 24852946
Drug: Xylitol candy
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol candy (7.5 g daily intake)
Study: 24852946
Drug: Sorbitol candy
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol candy (7.5 g daily intake)
Study: 22381809
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and prednisone dual therapy
Study: 17609246
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment
Study: 110212
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily (A‐50)
Study: 110212
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg daily (A‐100)
Study: 30851050
Drug: Both toothpaste
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both toothpaste formulations
Study: 26285327
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser irradiation of the blood in addition to traditional medicamental treatment (n = 102)
Study: 26285327
Drug: Traditional medicamental
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medicamental treatment alone (Control group, n = 30)
Study: 15100337
Drug: Guideline implementation
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline implementation intervention including a tutorial for intake clinicians, group and individual performance feedback, use of a modified vital signs stamp, offer of free nicotine replacement therapy, and proactive telephone counseling.
Study: 9364699
Drug: Virosome-formulated influenza
Normalized name: influenza, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome-formulated influenza vaccine
Study: 9364699
Drug: Subunit influenza
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit influenza vaccine
Study: 2388129
Drug: VK1 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK1 (20 mg orally)
Study: 2388129
Drug: VK2 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK2 (20 mg orally)
Study: 2388129
Drug: VK1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK1 and VK2 (20 mg orally)
Study: 6790990
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation (nonactivated prothrombin-complex concentrate)
Study: 31116187
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 mm dental implants with a nanostructured calcium‐incorporated titanium surface
Study: 31116187
Drug: 10-mm or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mm or longer implants in augmented bone
Study: 31116187
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants in mandibles
Study: 31116187
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants in maxillae
Study: 22198635
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1-mg reproterol and 2-mg disodium cromoglycate (DSCG)
Study: 22198635
Drug: Short-acting β-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β-agonist reproterol alone
Study: 18449549
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of misoprostol vaginally (self administered) 4‐6 h prior to hysteroscopy
Study: 17697036
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol plus 30 mg dextromethorphan
Study: 15370724
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron daily intravenous bolus injection for 5 days
Study: 1482431
Drug: Preincisional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preincisional lidocaine infiltration (1% lidocaine, 40 mL)
Study: 1482431
Drug: Postincisional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postincisional lidocaine infiltration (1% lidocaine, 40 mL)
Study: 2861315
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 to 1.2 mg intravenously)